Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCT-598 in advanced solid tumors
NCT07358806Phase 1Recruiting
- Sponsor
- Oscotec Inc.
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of KNP-502 in solid tumor, breast cancer, head and neck cancer (HNC) and 4 more, sponsored by Oscotec Inc. Primary endpoints: Adverse Events at 2 years, Dose-Limiting Toxicities at 2 years and 1 more. Started Dec 2025; status: recruiting.
02
Drugs
KNP-502
03
Conditions
solid tumorbreast cancerhead and neck cancer (HNC)non-small cell lung cancer (NSCLC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07358806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07358806.